Literature DB >> 21652677

Blood doping and its detection.

Wolfgang Jelkmann1, Carsten Lundby.   

Abstract

Hemoglobin mass is a key factor for maximal exercise capacity. Some athletes apply prohibited techniques and substances with intent to increase hemoglobin mass and physical performance, and this is often difficult to prove directly. Autologous red blood cell transfusion cannot be traced on reinfusion, and also recombinant erythropoietic proteins are detectable only within a certain timeframe. Novel erythropoietic substances, such as mimetics of erythropoietin (Epo) and activators of the Epo gene, may soon enter the sports scene. In addition, Epo gene transfer maneuvers are imaginable. Effective since December 2009, the World Anti-Doping Agency has therefore implemented "Athlete Biologic Passport Operating Guidelines," which are based on the monitoring of several parameters for mature red blood cells and reticulocytes. Blood doping may be assumed, when these parameters change in a nonphysiologic way. Hematologists should be familiar with blood doping practices as they may play an important role in evaluating blood profiles of athletes with respect to manipulations, as contrasted with the established diagnosis of clinical disorders and genetic variations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21652677     DOI: 10.1182/blood-2011-02-303271

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  The evolving science of detection of 'blood doping'.

Authors:  Carsten Lundby; Paul Robach; Bengt Saltin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Haematological rather than skeletal muscle adaptations contribute to the increase in peak oxygen uptake induced by moderate endurance training.

Authors:  David Montero; Adrian Cathomen; Robert A Jacobs; Daniela Flück; Jeroen de Leur; Stefanie Keiser; Thomas Bonne; Niels Kirk; Anne-Kristine Lundby; Carsten Lundby
Journal:  J Physiol       Date:  2015-09-14       Impact factor: 5.182

3.  Doping Attitudes and Covariates of Potential Doping Behaviour in High-Level Team-Sport Athletes; Gender Specific Analysis.

Authors:  Damir Sekulic; Enver Tahiraj; Milan Zvan; Natasa Zenic; Ognjen Uljevic; Blaz Lesnik
Journal:  J Sports Sci Med       Date:  2016-12-01       Impact factor: 2.988

4.  Ex vivo erythrocyte generation and blood doping.

Authors:  Giovanni Lombardi; Giuseppe Banfi; Giuseppe Lippi; Fabian Sanchis-Gomar
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

5.  Establishment of two quantitative nested qPCR assays targeting the human EPO transgene.

Authors:  E W I Neuberger; I Perez; C Le Guiner; D Moser; T Ehlert; M Allais; P Moullier; P Simon; R O Snyder
Journal:  Gene Ther       Date:  2016-01-11       Impact factor: 5.250

6.  Gender- and Sport-Specific Associations Between Religiousness and Doping Behavior in High-Level Team Sports.

Authors:  Milan Zvan; Natasa Zenic; Damir Sekulic; Mladen Cubela; Blaz Lesnik
Journal:  J Relig Health       Date:  2017-08

Review 7.  Investigation and Management of Erythrocytosis.

Authors:  Mary Frances McMullin
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

8.  Changes in hemoglobin profile reflect autologous blood transfusion misuse in sports.

Authors:  Nicola Lamberti; Alessia Finotti; Jessica Gasparello; Ilaria Lampronti; Christel Zambon; Lucia Carmela Cosenza; Enrica Fabbri; Nicoletta Bianchi; Francesca Dalla Corte; Maurizio Govoni; Roberto Reverberi; Roberto Gambari; Fabio Manfredini
Journal:  Intern Emerg Med       Date:  2018-03-23       Impact factor: 3.397

9.  Evaluation of serum markers for improved detection of autologous blood transfusions.

Authors:  Holly D Cox; Geoffrey D Miller; Auriella Lai; Dan Cushman; Tomas Ganz; Daniel Eichner
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

10.  Diagnosis and management of congenital and idiopathic erythrocytosis.

Authors:  Mary Frances McMullin
Journal:  Ther Adv Hematol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.